VANCOUVER, British Columbia — September 16, 2026
AbCellera announced that it will present Phase 2 efficacy and safety data for ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, scheduled for September 30 to October 3, 2026, in Rio de Janeiro, Brazil. The oral presentation will provide interim results from the clinical development program evaluating ABCL635 in postmenopausal women with moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes. The presentation, titled “Interim Results of a Phase 1/2 Study of ABCL635, a First-in-Class NK3R Monoclonal Antibody for the Treatment of Vasomotor Symptoms,” is scheduled for October 1 during the Symptoms of Menopause 1 session. The planned data disclosure represents an important clinical development milestone for AbCellera as it advances its first pipeline program from its GPCR and ion channel platform into clinical-stage development.
ABCL635 Targets NK3R for Non-Hormonal VMS Treatment
ABCL635 is an investigational monoclonal antibody designed to target neurokinin 3 receptor (NK3R), a clinically validated G protein-coupled receptor expressed on KNDy neurons in the hypothalamus. By targeting this pathway, AbCellera is developing ABCL635 as a potential non-hormonal and long-acting treatment for moderate-to-severe VMS associated with menopause. The company advanced ABCL635 into clinical development in July 2025, making it the first program from its GPCR and ion channel discovery platform to enter the clinic. The Phase 2 program, registered as NCT07118891, is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of ABCL635 in postmenopausal women experiencing moderate-to-severe menopausal VMS. The upcoming presentation is expected to provide additional insight into the candidate’s clinical profile as AbCellera evaluates its potential role in women’s health.
Phase 2 Program Addresses Significant Menopause Treatment Need
The ABCL635 program is focused on a common and persistent symptom of menopause that can substantially affect daily life. Vasomotor symptoms, including hot flashes and night sweats, are reported to affect up to 80% of women, with many experiencing moderate-to-severe symptoms. These episodes can contribute to disrupted sleep and affect concentration, energy, mood, work, social activities and relationships. AbCellera estimates that approximately 12 million women in the United States experience moderate-to-severe VMS, with more than six million seeking treatment. The Phase 2 study is therefore evaluating ABCL635 in a clinically relevant population while assessing both efficacy and safety under controlled conditions. The presentation at the IMS World Congress on Menopause will provide the company an opportunity to communicate clinical findings to specialists in menopause care and support further evaluation of the NK3R-targeted approach.
Advertisement
AbCellera Expands Clinical Antibody Development Pipeline
The ABCL635 program represents an important expansion of AbCellera’s strategy from antibody discovery into proprietary clinical-stage drug development. The company is developing first-in-class antibody-based medicines across endocrinology, women’s health, immunology and oncology, with ABCL635 serving as a lead example of its approach to translating target discovery into therapeutic programs. Further development of ABCL635 will depend on the emerging clinical efficacy and safety data and the company’s assessment of subsequent regulatory and development steps. The planned Phase 2 data presentation also strengthens AbCellera’s presence in women’s health, an area where non-hormonal approaches to menopause-related symptoms are receiving increasing clinical attention. With interim Phase 2 results scheduled for presentation at a major international menopause meeting, AbCellera is advancing ABCL635 as a potential long-acting NK3R-targeted therapy while expanding its broader clinical antibody pipeline.
Source:AbCellera,, press release
